Belantamab mafodotin-blmf (BLENREP)
Criteria for Use
September 2026

VHA Pharmacy Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If ANY of the following are selected, the patient will NOT meet criteria for belantamab.

- ☐ Absolute Neutrophil Count < 1000/mm^3 unless Duffy Null phenotype
- ☐ Platelet count < 75,000/mm^3
- ☐ Creatinine clearance < 30 ml/min
- ☐ Moderate to severe hepatic impairment (Child Pugh B, C or NCI Organ Dysfunction Working Group Classification)
- ☐ Corneal epithelial disease, except mild punctate keratopathy
- ☐ Active or uncontrolled infection
- ☐ Pregnancy
- ☐ Lactating
- ☐ Refractory or intolerant to bortezomib
- ☐ Received prior treatment with a BCMA-targeting therapy (i.e. idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, elranatamab, linvoseltamab)

Inclusion Criteria

All the following must be selected to meet criteria.

- ☐ Multiple Myeloma diagnosis
- ☐ Documented myeloma disease progression on at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent
- ☐ Care provided by a VA or VA Community Care hematology/oncology provider
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented
- ☐ Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- ☐ All REMS requirements have been met for provider, patient, and healthcare setting
- ☐ Co-management with eye care professional (i.e. ophthalmologist or optometrist) required for monitoring
- ☐ Eye care professional provided drug information prior to first dose[1]
- ☐ Baseline eye exam including visual acuity and slit lamp within 3 weeks of first dose
- ☐ Patient able to administer preservative-free lubricant eye drops at least 4 times daily starting with first infusion and continuing until course of therapy completion
- ☐ Patient able to avoid wearing contact lenses during treatment, unless directed by eye care professional

[1] Drug information may include but is not limited to Drug monograph, CFU, Prescribing Information, REMS material

Additional Inclusion Criteria – Select If Applicable

- ☐ For females who can become pregnant: Pregnancy must be excluded prior to receiving belantamab.
- ☐ For females who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 4 months after stopping treatment
- ☐ For males with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 6 months after stopping treatment

☐ For females who are lactating / providing breastmilk to an infant or planning to do so: Counseling provided advising women not to breastfeed during therapy and for 3 months after stopping treatment.

Original: Sept 2026

Contact: B. Heron, National Program Manager, VHA Pharmacy Services – Formulary Management (12PBM)

Portions of these documents or records, or information contained herein, which resulted from Pharmacy Benefits Management Drug Usage Evaluation and Utilization Review activities, may be considered confidential and privileged under the provisions of 38 U.S.C. 5705 and its implementing regulations. In such cases, this material shall not be disclosed to anyone without authorization as provided for by that law of its regulations. The statute provides for fines up to $20,000 for unauthorized disclosure.